Pharmaceutical companies will accelerate adoption of adaptive clinical trial designs, according to the Tufts Center for Drug Development, to reduce clinical development timelines and costs while increasing program success rates.

from Forbes – Tech http://ift.tt/1pLxmUy
via IFTTT